Generated by Meeveem AI
"Mytos automates stem cell therapy production for regenerative medicine at scale"
Mytos builds automation technology for stem cell manufacturing. The company's iDEM system automates every step of cell culture, from coating and seeding to imaging, passaging and harvesting. This enables biotech companies to produce regenerative medicines consistently, at scale and at lower cost per dose. Mytos also operates an automated CDMO housed within CGT Catapult's facility. The technology serves clinical stage companies developing therapies for brain, eye and bone conditions. Partners include Aspen Neuroscience working on Parkinson's disease, plus StemSight, Rinri Therapeutics and Novadip. By removing scalability and cost barriers of manual production, Mytos helps biotech firms move faster from trials to commercial manufacturing.
42
Team Members
2016
Founded
Medical Devices
Sector
On-Site
Work Environment
Regenerative medicines reach millions of patients worldwide, with automated manufacturing enabling treatments for previously incurable conditions affecting the brain, eyes and bones.
At Mytos, our mission is to scale regenerative medicine to millions of patients by removing the scalability and cost challenges of manual cell manufacturing.